HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30, where the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.
Questions around this news
Which conferences will HeartBeam executives attend in March 2026?
The company’s CEO and CFO are scheduled for the virtual Oppenheimer healthcare and medtech conference on March 16–17, with a webcast presentation on March 16. They are also due at the ROTH Conference in Dana Point on March 23–24, where the CEO is slated to take part in a panel. Several company leaders plan to attend the American College of Cardiology’s annual meeting, ACC.26, on March 28–30.
What will HeartBeam present or demonstrate at ACC.26?
At the cardiology meeting, the company plans to display its FDA-cleared HeartBeam System and show physicians and prospective industry partners a working prototype of an extended-wear patch intended to capture 12-lead ECG information. The release identifies the patch as a prototype; it does not describe a commercial launch or provide further technical specifications for it.
What does a 12-lead ECG measure?
An electrocardiogram, or ECG, records the heart’s electrical activity through sensors placed on the body. A 12-lead ECG presents that activity from multiple viewpoints, helping clinicians assess rhythm and electrical patterns. The term “lead” refers to a view of the heart’s electrical signals, rather than to a separate physical wire in every case.
What is FDA clearance for a medical device?
FDA clearance is a regulatory status for certain medical devices that have been reviewed through a pathway assessing whether they are substantially equivalent to an appropriate legally marketed device. It is distinct from FDA approval, which generally applies to devices reviewed under a different, more extensive process. The specific permitted use depends on the agency’s clearance decision.
To view the full press release, visit https://ibn.fm/tnwvK
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1) . The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- HeartBeam, Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Event
People
- Robert EnoCEO
- Timothy CruickshankCFO
- Branislav VajdicFounder and President
- Bryan HumbargerChief Commercial Officer
Products and programs
SEC filings
Earlier from HeartBeam, Inc.
- HeartBeam (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection
- HeartBeam (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio
- HeartBeam (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target
- HeartBeam (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer
- FDA Clearance for HeartBeam (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup
